Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
02 nov. 2022 16h01 HE
|
Rubius Therapeutics
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius...
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
19 sept. 2022 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red...
Rubius Therapeutics Announces Strategic Update
13 sept. 2022 07h00 HE
|
Rubius Therapeutics
Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 ...
Rubius Therapeutics to Provide Strategic Update
12 sept. 2022 16h30 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create...
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
09 août 2022 08h00 HE
|
Rubius Therapeutics
New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1...
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
26 juil. 2022 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
14 juil. 2022 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
22 juin 2022 08h00 HE
|
Rubius Therapeutics
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression Findings...
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
01 juin 2022 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
26 mai 2022 17h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...